tadalafil has been researched along with Dyslipidemias in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koka, S; Kukreja, RC; Xi, L | 1 |
| Bassi, P; Bonanni, G; Cella, G; De Bon, E; Saggiorato, G | 1 |
2 other study(ies) available for tadalafil and Dyslipidemias
| Article | Year |
|---|---|
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dyslipidemias; Heart; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide; Nitrites; Phosphodiesterase 5 Inhibitors; Tadalafil; Ventricular Function, Left | 2020 |
Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study.
Topics: Analysis of Variance; Blood Platelets; Carbolines; Cyclic AMP; Cyclic GMP; Dyslipidemias; E-Selectin; Endothelium, Vascular; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; P-Selectin; Phosphodiesterase Inhibitors; Pilot Projects; Risk Factors; Smoking; Tadalafil | 2010 |